Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
|Videos|September 29, 2020
An Opportunity for Growth
Author(s)Helen Lavretsky, MD, MS
Dr Lavretsky invites us to use the pandemic as a chance to build good habits, explore spiritual avenues, and start new routines.
Advertisement
Dr Lavretsky is Professor of Psychiatry, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA.
Advertisement
Related to this article
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
2
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
3
Dosing MDD Therapies in Medically Complex Patients: Metabolism and Interactions
4
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
5